2. Search Result
Search Result
Results for "

KRT1

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

2

Peptides

2

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS07433
    KRT1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KRT1 Human Pre-designed siRNA Set A contains three designed siRNAs for KRT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KRT1 Human Pre-designed siRNA Set A
    KRT1 Human Pre-designed siRNA Set A
  • HY-RS19346
    Krt1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Krt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Krt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Krt1 Mouse Pre-designed siRNA Set A
    Krt1 Mouse Pre-designed siRNA Set A
  • HY-P10789
    P160 peptide

    		Microtubule/Tubulin Cancer
    The P160 peptide is a breast cancer-targeting peptide that binds to the keratin 1 (KRT1) receptor on breast cancer cells, with a Kd of approximately 1.1 μM, demonstrating significant potential for targeted drug delivery to breast cancer cells. The P160 peptide enhances the cellular uptake and anticancer activity of the pro-apoptotic antimicrobial peptide MccJ25 (microcin J25). The P160 peptide can be used in cancer research [1].
    P160 peptide
  • HY-P10790
    Breast cancer targeting peptide 18–4

    		Microtubule/Tubulin Cancer
    Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively [1].
    Breast cancer targeting peptide 18–4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: